Article Cited by others

REVIEW ARTICLE

Mouse models of estrogen receptor-positive breast cancer

Mohibi Shakur, Mirza Sameer, Band Hamid, Band Vimla

Year : 2011| Volume: 10| Issue : 1 | Page no: 35-35

   This article has been cited by
 
1 Survival Analysis of Breast Cancer Subtypes in Patients With Spinal Metastases
Miao Wang,Anders Bonde Jensen,Soeren Smith Morgen,Chun Sen Wu,Ming Sun,Haisheng Li,Benny Dahl,Cody Eric BŁnger
Spine. 2014; 39(19): 1620
[Pubmed]  [Google Scholar] [DOI]
2 Genetically engineered ER†-positive breast cancer mouse models
S. A. Dabydeen,P. A. Furth
Endocrine Related Cancer. 2014; 21(3): R195
[Pubmed]  [Google Scholar] [DOI]
3 Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis
C. E. Cano,T. Hamidi,M. N. Garcia,D. Grasso,C. Loncle,S. Garcia,E. Calvo,G. Lomberk,N. Dusetti,L. Bartholin,R. Urrutia,J. L. Iovanna
Gut. 2014; 63(6): 984
[Pubmed]  [Google Scholar] [DOI]
4 Oxidative stress specifically downregulates survivin to promote breast tumour formation
Pervin, S. and Tran, L. and Urman, R. and Braga, M. and Parveen, M. and Li, S.A. and Chaudhuri, G. and Singh, R.
British Journal of Cancer. 2013; 108(4): 848-858
[Pubmed]  [Google Scholar]
5 Treatment of estrogen receptor-positive breast cancer
Lumachi, F. and Brunello, A. and Maruzzo, M. and Basso, U. and Basso, S.M.M.
Current Medicinal Chemistry. 2013; 20(5): 596-604
[Pubmed]  [Google Scholar]
6 CYP 17 and estrogen receptor a gene polymorphisms: association with breast cancer susceptibility and clinicopathological parameters in a cohort of Egyptian patients
Nadida Gohar,Dina El Gayar,Marianne Samir M. Issac,Mohammed Shehata,Yasmine Khater,Ezzat S. Saad
Comparative Clinical Pathology. 2013;
[Pubmed]  [Google Scholar] [DOI]
7 Oxidative stress specifically downregulates survivin to promote breast tumour formation
S Pervin,L Tran,R Urman,M Braga,M Parveen,S A Li,G Chaudhuri,R Singh
British Journal of Cancer. 2013; 108(4): 848
[Pubmed]  [Google Scholar] [DOI]
8 Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients
Sameer Mirza,Emad A. Rakha,Alaa Alshareeda,Shakur Mohibi,Xiangshan Zhao,Bryan J. Katafiasz,Jun Wang,Channabasavaiah Basavaraju Gurumurthy,Aditya Bele,Ian O. Ellis,Andrew R. Green,Hamid Band,Vimla Band
Breast Cancer Research and Treatment. 2013; 137(3): 721
[Pubmed]  [Google Scholar] [DOI]

 

Read this article